
ABOUT POLYPLUS
Polyplus SA is the leading biotechnology company that supports Gene and Cell therapy, biologics manufacturing and life science research with innovative nucleic acid transfection solutions. Polyplus strengths are 20 years of experience in manufacturing transfection solutions with tailored scientific and regulatory support to accelerate research. Based in the Science Park close to Strasbourg (France), Polyplus offers an extensive and growing range of transfection reagents available worldwide.
CONTACT INFORMATION
Polyplus
1251 Ave of the Americas 3rd Fl
New YorK, NY 10020
UNITED STATES
BROCHURES AND DATASHEETS
PODCASTS & WEBINARS
FEATURED ARTICLES
-
Meet the demand for AAV-based gene therapies using design-of-experiment and fit-for-purpose plasmids and transfection reagents.
-
Why is this transfection reagent often chosen for virus production runs in the most adherent and suspension cell culture systems and what are it's benefits?
-
Explore this discussion amongst experts about how to develop robust, scalable, and cost-effective processes that yield high titers of high-quality viral vectors.
-
Discover approaches that make gene therapies accessible to more patients by overcoming current issues limiting the available capacity for viral-vector manufacturing.
-
Discover how our transfection reagent demonstrates robust, non-toxic and efficient gene expression delivery in hard-to-transfect primary hMSCs, mESCs and induced pluripotent stem cells.
-
In this study we demonstrate a delivery mechanism that is a simple and ready-to-use transfection reagent that leads to outstanding transfection efficiencies in known to be hard-to-transfect stem cells.
-
Improving this one aspect of viral vector manufacturing can help enable scalable production of high-quality vectors with acceptable costs and timelines.
-
Industry experts offer advice on the use of GMP raw materials for viral vector manufacturing along with the key points of evolution relating to regulatory guidance and requirements for viral vector production.
-
The conventional approach to plasmid DNA design and construction is not amenable to fine-tuning the structure and properties of the molecules. We explore a method for the design and construction of plasmid DNA from scratch.
-
A regulatory affairs specialist discusses best practices and challenges for manufacturing biologics under GMPs and reviews details around the EU’s revision to Annex 1.
-
By leveraging a standardized, scalable platform approach for viral vector manufacturing, including the transient transfection step, timelines can be accelerated to bring next-generation therapies to market.
-
It’s worth carefully assessing the eligibility of an AM before as early as possible before entering clinical testing as it will result in a significant gain of time and money.
-
Read how optimizing the transfection step during upstream process development leverages tremendous benefits on overall costs, robustness and scalability of an AAV production platform.
-
To achieve high transient protein yields, TGE is dependent on an efficient transfection method. We review a system for optimal protein production in several commercially available suspension CHO cell lines.
-
We review 4 main strategies for current COVID-19 vaccines currently in development: virus-based vaccines, nucleic acid-based vaccines, protein-based vaccines and viral vector vaccines.
-
The expression of recombinant proteins has evolved to allow the development of innovative diagnostic and therapeutic applications.
-
We review the four main types of viral vectors utilized for gene therapy applications and chemical transfection reagents options for efficient production of viral vectors at all scales.
-
We discuss the process of transfection and highlight two highly effective vectors for both in vitro and in vivo gene therapy applications.
-
Explore how lentiviral vectors can be used across a range of clinically relevant cell-based gene therapies and highlight a transfection reagent has become the gold standard for efficient, reproducible and cost-effective lentivirus manufacturing.
-
It is extremely important to confirm the identity, purity, and quality of raw materials prior to starting the viral vector manufacturing to ensure patient safety is being considered and safeguarded from the start of the manufacturing process.